BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 203.2 EUR | -0.44% |
|
+11.86% | -13.46% |
| Apr. 30 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
| Apr. 29 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
| Sales 2024 * | 9.53B 8.89B | Sales 2025 * | 9.55B 8.91B | Capitalization | 31.47B 29.37B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.9B 1.77B | Net income 2025 * | 2.22B 2.07B | EV / Sales 2024 * | 3.6 x |
| Net Debt 2024 * | 2.87B 2.67B | Net Debt 2025 * | 549M 512M | EV / Sales 2025 * | 3.35 x |
| P/E ratio 2024 * |
16.4
x | P/E ratio 2025 * |
14.3
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | -0.44% | ||
| 1 week | +11.86% | ||
| Current month | +2.11% | ||
| 1 month | +2.11% | ||
| 3 months | -11.03% | ||
| 6 months | -9.20% | ||
| Current year | -13.46% |
1 week
181.45
204.10
1 month
177.65204.10
Current year
177.65245.60
1 year
177.65309.80
3 years
174.26351.70
5 years
174.26351.70
10 years
174.26447.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 203.2 | -0.44% | 316 |
| 24-04-29 | 204.1 | +5.45% | 436 |
| 24-04-26 | 193.6 | +4.17% | 238 |
| 24-04-25 | 185.8 | -1.95% | 174 |
| 24-04-24 | 189.5 | +4.29% | 539 |
Delayed Quote Xetra, April 30, 2024 at 11:35 am EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
216.1
USD
Average target price
286
USD
Spread / Average Target
+32.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| +57.86% | 25.27B | |
| -13.58% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.53% | 7.94B | |
| +1.55% | 7.58B |
- Stock Market
- Equities
- BIIB Stock
- IDP Stock
